Detalhe da pesquisa
1.
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
Diabetes Obes Metab
; 26(1): 215-223, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814517
2.
Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.
Diabetes Obes Metab
; 25(1): 89-97, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054737
3.
Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Diabetes Obes Metab
; 24(2): 187-195, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605142
4.
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
Diabetes Obes Metab
; 24(2): 196-203, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595812
5.
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.
Diabetes Obes Metab
; 22(10): 1799-1807, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32488923
6.
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
Diabetes Obes Metab
; 22(10): 1789-1798, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436641
7.
Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trials.
J Diabetes Complications
; 38(1): 108648, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38035641
8.
Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
Clin Ther
; 44(6): 836-847, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577602
9.
Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data.
Clin Pharmacokinet
; 60(11): 1423-1434, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34041713
10.
Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.
Diabetes Ther
; 12(2): 569-580, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33458803
11.
Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects.
Diabetes Ther
; 11(8): 1709-1720, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32535742
12.
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Clin Ther
; 42(9): 1762-1777.e4, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900535
13.
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial.
Clin Pharmacokinet
; 59(12): 1589-1599, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468447
14.
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study.
Clin Pharmacokinet
; 59(12): 1601-1610, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468448
15.
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Biol Psychiatry
; 61(5): 713-9, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16996485
16.
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
J Clin Psychiatry
; 77(5): 635-42, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27035159
17.
Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Curr Med Res Opin
; 31(6): 1179-89, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25894953
18.
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder.
Drugs Context
; 4: 212279, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26005493
19.
A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
J Affect Disord
; 167: 215-23, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24995890
20.
A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
J Psychiatr Res
; 45(6): 748-55, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21511276